Surrozen Inc
SRZN
Get informed when a big investor buys or sells
+ FollowMarket Cap$195.98M
Close$
$10.83
55.9% downside
Current Fair Value
55.9% downsideOvervalued by 55.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $195.98 Million |
|---|---|
| Enterprise Value | $95.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-32.37 |
| Beta | 0.59 |
| Outstanding Shares | 10,949,000 |
Return
| Return on Equity | 77.32% |
|---|---|
| Return on Assets | -178.16% |
| Return on Invested Capital | -93.39% |
Valuation & Multiples
| P/E Ratio | -0.84 |
|---|---|
| PEG | 0.84 |
| Price to Sales | - |
| Price to Book Ratio | -0.95 |
| Enterprise Value to Revenue | 12.79 |
| Enterprise Value to EBIT | -0.92 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-1.05
Average shareholder expectationRevenue Estimate
$5.33 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-1.35
Average shareholder expectationRevenue Estimate
$475,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 81.59%▼ 1.73% |
|---|---|
| Total Invested | $258.37M▲ 68.60% |
| Investors Holding | 58▲ 4.00% |
ESG Score
No data
About Surrozen Inc
2,021 employeesSurrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs a...